November 14, 2016 / 11:02 PM / 23 days ago

BRIEF-Viiv Healthcare Says Late-Stage HIV Treatment Study Met Primary Endpoint

March 9 (Reuters) - VIIV HEALTHCARE:

* VIIV HEALTHCARE PRESENTS POSITIVE 48-WEEK DATA FROM PHASE III STUDY SHOWING EVERY-TWO-MONTH REGIMEN OF INVESTIGATIONAL LONG-ACTING, INJECTABLE CABOTEGRAVIR AND RILPIVIRINE HAS SIMILAR EFFICACY TO ONCE-MONTHLY DOSING

* VIIV HEALTHCARE - PHASE III ATLAS-2M STUDY OF CABOTEGRAVIR AND JANSSEN’S RILPIVIRINE FOR HIV TREATMENT MET PRIMARY ENDPOINT AT WEEK 48

* VIIV HEALTHCARE - TREATMENT WITH CABOTEGRAVIR AND RILPIVIRINE WAS GENERALLY WELL-TOLERATED ACROSS BOTH STUDY ARMS

* VIIV HEALTHCARE- IN 2-MONTH ARM, RATES OF SERIOUS ADVERSE EVENTS & WITHDRAWALS DUE TO AE WERE LOW, SIMILAR TO THOSE EXPERIENCED IN 1-MONTH ARM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below